iCAD, Inc. (Nasdaq: ICAD), an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer, today announced that Company management will participate in Craig-Hallum’s 4 th Annual Alpha Select Conference taking place on September 26, 2013 at the Convene Conference Center in New York City. Ken Ferry, iCAD’s President and Chief Executive Officer, will deliver a corporate overview at 3:45 p.m. Eastern time.
Mr. Ferry’s presentation will be webcast live at http://wsw.com/webcast/ch3/iCAD and on the Investor Relations section of the Company’s website at www.icadmed.com, where it will also be archived for 90 days following the live presentation.
About The Alpha Select ConferenceEntering its fourth year, the Craig-Hallum Alpha Select Conference has earned a reputation among Craig-Hallum’s clients as an important idea generation opportunity. Attending companies have been individually selected by the Craig-Hallum research team and are either currently on the Alpha Select List or display characteristics that are consistent with the Alpha Select List. The format of the conference is focused around 1-on-1 meetings with attending companies preparing an open half hour presentation and spending the remainder of the day in discussions with individual investors. With an Investor/Company personnel ratio under 4:1, investors have a high degree of access to company management.
About iCAD, Inc.iCAD is a leading provider of advanced image analysis, workflow solutions and radiation therapies for the early identification and treatment of common cancers. iCAD offers a comprehensive range of high-performance, upgradeable CAD solutions for mammography and advanced image analysis and workflow solutions for Magnetic Resonance Imaging, for breast and prostate cancers and Computed Tomography for colorectal cancer. iCAD’s Xoft System offers radiation treatment for early-stage breast cancer that can be administered in the form of intraoperative radiation therapy or accelerated partial breast irradiation. The Xoft System is also cleared for the treatment of non-melanoma skin cancer, cervical cancer and endometrial cancer. For more information, call 877-iCADnow, or visit www.icadmed.com."Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: Certain statements contained in this News Release constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve a number of known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, but are not limited to, the Company’s ability to defend itself in litigation matters, the Company’s ability to identify a replacement for the Axxent FlexiShield Mini, the risks relating to the Company’s acquisition of Xoft including, the expected benefits of the acquisition may not be achieved in a timely manner, or at all; the Xoft business operations may not be successfully integrated with iCAD’s and iCAD may be unable to achieve the expected synergies, business and strategic objectives following the transaction, the risks of uncertainty of patent protection; the impact of supply and manufacturing constraints or difficulties; product market acceptance; possible technological obsolescence; increased competition; customer concentration; and other risks detailed in the Company’s filings with the Securities and Exchange Commission. The words “believe”, “demonstrate”, “intend”, “expect”, “estimate”, “anticipate”, “likely”, and similar expressions identify forward-looking statements. Readers are cautioned not to place undue reliance on those forward-looking statements, which speak only as of the date the statement was made. The Company is under no obligation to provide any updates to any information contained in this release. For additional disclosure regarding these and other risks faced by iCAD, please see the disclosure contained in our public filings with the Securities and Exchange Commission, available on the Investors section of our website at http://www.icadmed.com and on the SEC’s website at http://www.sec.gov .